Media.Player

NOVEL THERAPEUTIC METHODS FOR TREATING INFLAMMATION AND IMMUNE SYSTEM DISORDERS

總結

A method for treating inflammatory and immune conditions by modulating TNF-a and nitric oxide production is provided. Said [method comprises administering a compound having the following formula (I):

附加資料

Patent Number: US20110177106A1
Application Number: US13005301A
Inventor: LAU, Allan Sik Yin | YANG, Lai Hung Cindy | OR, Cho Tsun
Priority Date: 23 Nov 2009
Priority Number: US20110177106A1
Application Date: 12 Jan 2011
Publication Date: 21 Jul 2011
IPC Current: A61K0031365 | A61P000300 | A61P000900 | A61P000910 | A61P002500 | A61P002516 | A61P002528 | A61P002900 | A61P003100 | A61P003702 | A61P003706 | A61P003708 | G01N003353
US Class: 4241841 | 4242781 | 436501 | 514470
Title: Novel Therapeutic Methods for Treating Inflammation and Immune System Disorders
Usefulness: Novel Therapeutic Methods for Treating Inflammation and Immune System Disorders
Summary: For treating a subject to reduce inflammation or to modulate an immune response; or having a condition associated with tumor necrosis factor α overproduction, where the subject is a human (claimed); to reduce nitric oxide production; TNF-α mRNA stability; to treat a condition selected from infection, inflammation caused by an environmental toxin, an autoimmune condition, neurodegenerative disease, cardiovascular disease, cerebrovascular disease, intestinal inflammation, post-infection associated neurological neuralgia, shingles, chronic fatigue syndrome, inflammation caused by concurrent infection or immunological over-reaction to pathogen invasion, allergy, graft rejection, pathological immune cell proliferation or activity, and respiratory inflammation; to treat a condition selected from ischemic stroke, rheumatoid arthritis, psoriasis, cardiovascular disease, cerebrovascular disease, inflammatory bowel disorder, septic shock, graft vs host rejection, varicella zoster infection, herpes simplex infection, cytomegalovirus infection, herpes simplex virus-8 infection, neuralgia, and neurasthenia associated with herpes zoster reactivation; to treat or ameliorate inflammation associated with atherosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders including cerebro-vascular disease (stroke), respiratory distress syndrome and other cardiopulmonary diseases; and to treat or ameliorate inflammation associated with peptic ulcer; ulcerative colitis, Crohn's Disease, irritable bowel syndrome, other inflammatory bowel conditions, and other diseases, conditions or disorders of the gastrointestinal tract; to treat or ameliorate inflammation associated with herpes zoster (shingles); posterior uveitis; intermediate uveitis; anterior uveitis; conjunctivitis; chorioretinitis; uveoretinitis; optic neuritis; intraocular inflammation, such as retinitis and cystoid macular edema; sympathetic ophthalmia; scleritis; retinitis pigmentosa; immune and inflammatory components of degenerative fondus disease; inflammatory components of ocular trauma; ocular inflammation caused by infection; proliferative vitreoretinopathies; acute ischemic optic neuropathy; excessive scarring; immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, conditions or disorders.
Novelty: Treating human to reduce inflammation or to modulate immune response or having condition associated with tumor necrosis factor alpha overproduction, involves administering, to a subject, an isolated isobenzofuran-1-one compound

主要類別

診斷/治療

細分類別

其他疾病

申請號碼

US13005301A

國家/地區

香港